Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Saltzman

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2018
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancerRyoichi Matsunuma, Doug W Chan, Beom-Jun Kim, et al.
Nature Communications|January 11, 2022
Mutations in Hcfc1 and Ronin result in an inborn error of cobalamin metabolism and ribosomopathyTiffany Chern, Annita Achilleos, Xuefei Tong, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
The Journal of Clinical Investigation|October 24, 2023
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
Cell Reports. Medicine|August 1, 2025
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancerMatthew V Holt, Yongchao Dou, Meggie N Young, et al.
Iscience|January 9, 2023
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approachVarduhi Petrosyan, Lacey E Dobrolecki, Lillian Thistlethwaite, et al.
Nature Communications|January 29, 2020
Microscaled proteogenomic methods for precision oncologyShankha Satpathy, Eric J Jaehnig, Karsten Krug, et al.
Biorxiv : the Preprint Server for Biology|December 23, 2024
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy ResponsesJonathan T Lei, Lacey E Dobrolecki, Chen Huang, et al.
Cell|January 15, 2021
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancerElizabeth A Bowling, Jarey H Wang, Fade Gong, et al.
Cancer Discovery|August 8, 2025
Integrative proteogenomics and forward genetics reveals a novel mitotic vulnerability in triple-negative breast cancerNicholas J Neill, Shankha Satpathy, Karsten Krug, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2018
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancerRyoichi Matsunuma, Doug W Chan, Beom-Jun Kim, et al.
Nature Communications|January 11, 2022
Mutations in Hcfc1 and Ronin result in an inborn error of cobalamin metabolism and ribosomopathyTiffany Chern, Annita Achilleos, Xuefei Tong, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
The Journal of Clinical Investigation|October 24, 2023
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
Cell Reports. Medicine|August 1, 2025
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancerMatthew V Holt, Yongchao Dou, Meggie N Young, et al.
Iscience|January 9, 2023
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approachVarduhi Petrosyan, Lacey E Dobrolecki, Lillian Thistlethwaite, et al.
Nature Communications|January 29, 2020
Microscaled proteogenomic methods for precision oncologyShankha Satpathy, Eric J Jaehnig, Karsten Krug, et al.
Biorxiv : the Preprint Server for Biology|December 23, 2024
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy ResponsesJonathan T Lei, Lacey E Dobrolecki, Chen Huang, et al.
Cell|January 15, 2021
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancerElizabeth A Bowling, Jarey H Wang, Fade Gong, et al.
Cancer Discovery|August 8, 2025
Integrative proteogenomics and forward genetics reveals a novel mitotic vulnerability in triple-negative breast cancerNicholas J Neill, Shankha Satpathy, Karsten Krug, et al.
Pageof 12